title: Global experience with ixabepilone in breast cancer.
abstract: Ixabepilone approval in a number of countries across the world as monotherapy and in combination with capecitabine has led to widespread uptake in the later-line breast cancer setting. However, individualized data for ixabepilone in different ethnic groups are limited. Overall, data from small numbers of ethnic subgroups including Hispanic, Japanese and Chinese patients have revealed no clinically significant variation in the disposition, efficacy or tolerability of ixabepilone from that established in pivotal trials. Global use of ixabepilone, while usually along the lines of standard practice, may vary because of local regulatory decisions, clinical practice guidelines and cost considerations. Further information on the global patterns of use of ixabepilone will assist in optimizing the use of this novel therapy.
authors.affiliation: Cancer Genetics Program, Division of Hematology/Oncology, Northwestern University, 676 N St Clair St, Suite 850, Chicago, IL 60611, USA. v-kaklamani@northwestern.edu
authors.forename: Virginia G
authors.initials: VG
authors.lastname: Kaklamani
authors.forename: Binge H
authors.initials: BH
authors.lastname: Xu
authors.forename: Henry L
authors.initials: HL
authors.lastname: Gomez
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000453:epidemiology; D017277:Drug Approval; D034261:Epothilones / Q000009:adverse effects / Q000627:therapeutic use*; D005006:Ethnicity; D005260:Female; D014943:Global Health; D006801:Humans; D017410:Practice Guidelines as Topic
chemical_list: D000970:Antineoplastic Agents; D034261:Epothilones; C430592:ixabepilone